Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity
Internal and Emergency Medicine · 2026-11 · 21 (8) · 2941-2949
DOI: 10.1007/s11739-026-04499-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal and Emergency Medicine, online erschienen am 20.08.2026. Verfasst von Giuseppe Armentaro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Geriatrics Division, "Renato Dulbecco" University Hospital of Catanzaro, 88100, Catanzaro, Italy. Hauptthemen laut MEDLINE: Heart Failure, Obesity, Glucagon-Like Peptides, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli studi "Magna Graecia" di Catanzaro.
Abstract (Originalsprache)
Heart failure with preserved ejection fraction (HFpEF), obesity, type 2 diabetes mellitus are common in elderly patients and are associated with an increased risk of cognitive impairment (CoI). In these patients, the protective metabolic and vascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established. The aim of this study was to evaluate effects of one-year treatment with oral semaglutide versus DPP-4 inhibitors (DPP4i), as an add-on to the hypoglycaemic therapy, on the incidence of CoI in patients with HFpEF, obesity, and type 2 diabetes. 246 elderly outpatients were recruited and divided into two groups (oral semaglutide vs. DPP4i), accurately matched for age, sex, and body mass index (BMI). At one-year follow-up, 106 new cases of CoI were observed in the entire study population (43.1 events/100 patients/year). A significant difference was found between the two groups: 33 cases with oral semaglutide (26.8 events/100 patients/year) versus 73 cases with DPP4i (59.3 events/100 patients/year), p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geriatrics Division, "Renato Dulbecco" University Hospital of Catanzaro, 88100, Catanzaro, Italy.
- Department of Human Sciences and Promotion of Quality of Life, San Raffaele Open, University of Rome, Rome, Italy.
- IRCCS San Raffaele, Rome, Italy.
- Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, 88100, Catanzaro, Italy. velia.cassano@unicz.it.
- Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, 88100, Catanzaro, Italy.
- Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100, Catanzaro, Italy.
Förderung
- Università degli studi "Magna Graecia" di Catanzaro
Zitieren
APA
Armentaro, G., Vitale, C., Cassano, V., Panza, M., Gareri, I., Mirabelli, M., Succurro, E., Andreozzi, F., Brunetti, A., Savarese, G., Volterrani, M., Sesti, G., Rosano, G. M. C., & Sciacqua, A. (2026). Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity. Internal and Emergency Medicine, 21(8), 2941-2949. https://doi.org/10.1007/s11739-026-04499-4
Vancouver
Armentaro G, Vitale C, Cassano V, Panza M, Gareri I, Mirabelli M, et al. Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity. Internal and Emergency Medicine. 2026;21(8):2941-2949. doi:10.1007/s11739-026-04499-4
BibTeX
@article{Armentaro2026,
author = {Armentaro, Giuseppe and Vitale, Cristiana and Cassano, Velia and Panza, Marilisa and Gareri, Ilaria and Mirabelli, Maria and Succurro, Elena and Andreozzi, Francesco and Brunetti, Antonio and Savarese, Gianluigi and Volterrani, Maurizio and Sesti, Giorgio and Rosano, Giuseppe Massimo Claudio and Sciacqua, Angela},
title = {Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity},
journal = {Internal and Emergency Medicine},
year = {2026},
volume = {21},
number = {8},
pages = {2941--2949},
doi = {10.1007/s11739-026-04499-4}
}
EUVIMED